EVITA trial: vitamin C lowered deaths in clonal blood conditions (exploratory result)
In the small phase 2 EVITA randomized trial of oral vitamin C in clonal cytopenia and lower-risk myeloid cancers, the vitamin C group had 65% lower risk of death (11 vs 24 deaths) and fewer serious adverse events. Survival was exploratory and the primary endpoint of clonal growth showed no difference. The poster speculates relevance to CHIP and cardiovascular disease but calls it a big unproven leap.